nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings.
nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings.
复制标题
DOI：
10.1186/s40164-017-0066-5
复制
发表时间：
2017
影响因子：
10.9
通讯作者：
Brufsky A
中科院分区：
文献类型：
--
作者：
Brufsky A
本系统综述的目的是讨论nab-紫杉醇在乳腺癌中的最新研究和正在进行的试验，并检查nab-紫杉醇作为免疫肿瘤治疗的骨干的潜在作用。检索了PubMed和选定的会议论文集，以查找2013年至2015年期间发表的nab-紫杉醇在乳腺癌中的研究。纳入了所有II期和III期临床试验、回顾性分析和机构研究。还包括在ClinicalTrials.gov上列出的关于nab-紫杉醇的积极的、正在进行的II期或III期试验。63项研究，包括23项早期和30项转移性乳腺癌研究（一些研究无法按环境分类），被纳入本分析。新辅助白蛋白结合型紫杉醇治疗方案的试验报告病理完全缓解率为5.7 - 53%。转移性乳腺癌研究的中位总生存期范围为10.8至23.5个月，取决于剂量和方案。白蛋白结合型紫杉醇的不良事件特征与先前研究报告的不良事件特征大致相似。几项正在进行的试验正在评估白蛋白结合型紫杉醇在早期和转移性环境中的作用，包括与免疫肿瘤药物联合使用。 nab-Paclitaxel继续在乳腺癌中显示出有希望的疗效。最近的研究表明，在早期乳腺癌中，特别是在三阴性乳腺癌中，病理学完全缓解率很高，这是一个高度未满足需求的领域，并且在不同剂量和时间表中，转移性乳腺癌的总生存率令人鼓舞。正在进行的试验将进一步深入了解白蛋白结合型紫杉醇在乳腺癌中的作用，包括作为免疫肿瘤治疗（如检查点抑制剂）的潜在骨干化疗药物。
The purpose of this systematic review is to discuss recent studies and ongoing trials of nab-paclitaxel in breast cancer and to examine the potential role of nab-paclitaxel as a backbone for immuno-oncology therapies. PubMed and selected congress proceedings were searched for studies of nab-paclitaxel in breast cancer published between 2013 and 2015. All phase II and III clinical trials, retrospective analyses, and institutional studies were included. Active, ongoing, phase II or III trials on nab-paclitaxel that were listed on ClinicalTrials.gov were also included. Sixty-three studies, including 23 in early-stage and 30 in metastatic breast cancer (some studies not classifiable by setting), were included in this analysis. Trials of neoadjuvant nab-paclitaxel–containing regimens have reported pathological complete response rates ranging from 5.7 to 53%. Median overall survival in metastatic breast cancer studies ranged from 10.8 to 23.5 months, depending on dose and regimen. Adverse event profiles of nab-paclitaxel were generally similar to those reported from previous studies. Several ongoing trials are evaluating nab-paclitaxel in the early-stage and metastatic settings, including in combination with immuno-oncology agents. nab-Paclitaxel continues to demonstrate promising efficacy in breast cancer. Recent studies demonstrate high pathological complete response rates in early-stage breast cancer, particularly in triple-negative breast cancer, an area of high unmet need, and encouraging overall survival in metastatic breast cancer across doses and schedules. Ongoing trials will provide further insights into the role of nab-paclitaxel in breast cancer including use as a potential backbone chemotherapy agent for immuno-oncology therapies such as checkpoint inhibitors.